Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (a foreign private issuer) on August 12, 2019, for the month of August 2019. The filing incorporates by reference a press release dated August 12, 2019, regarding clinical trial progress.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document serves solely to disclose a corporate event via an attached press release.
Material Changes and Corporate Events
- Clinical Trial Update: The Safety Review Committee (SRC) issued a positive outcome regarding the company's clinical trial.
- Patient Enrollment: The company successfully transplanted its 9th clinical trial patient.
Guidance, Outlook, and Risks
The filing text does not contain specific financial guidance, management commentary on future performance, or a detailed discussion of risks and contingencies beyond the context of the clinical trial update. The press release is incorporated into the company's Registration Statements on Forms S-8 and F-3.
Key Facts for Investor Verification
- Verify the full text of the press release (Exhibit 99.1) for details on the Safety Review Committee's findings.
- Confirm the status of the 9th patient transplant and any subsequent safety data.
- Review the referenced Registration Statements (S-8 and F-3) for the full disclosure of the first three paragraphs of the press release.
- Note that no financial performance metrics are included in this specific filing.